In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angiotech acquires Device Company, Takes Control of its Destiny

Executive Summary

Ever since drug-eluting stents became such an overwhelming success, the health care products industry has been trying to wrap its arms around convergence opportunities, in which the combination of drugs and devices is worth more than the sum of the parts and pieces. The ongoing debate has been: which part of combination products is it better to own--the drug or the device? According to one company that would probably define itself as the only "pure play" in convergence, Angiotech Pharmaceuticals Inc., the answer is: both. Angiotech just acquired diversified device manufacturer AMI Holdings.
Advertisement

Related Content

Deal Statistics Quarterly, Q1 2006
Deal Statistics Quarterly, Q1 2006
Angiotech: Specialty Pharma in the Device World

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002705

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel